Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

There was some evidence of an improvement in PFS (HR 0.44 (95% CI: 0.18–1.10), P =0.079) and OS (HR 0.23 (95% CI: 0.05–1.03), P =0.055) for wild-type compared to anytime-mutated cancers ( Figure 1A and B , Table 6 ), although this did not reach statistical significance at the 5% level.

also in 111,027 other papers